Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) EBITDA Margin (2018 - 2025)

Exagen (XGN) has disclosed EBITDA Margin for 8 consecutive years, with 29.91% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 514.0% year-over-year to 29.91%, compared with a TTM value of 21.13% through Dec 2025, up 337.0%, and an annual FY2025 reading of 21.13%, up 337.0% over the prior year.
  • EBITDA Margin was 29.91% for Q4 2025 at Exagen, down from 17.98% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 15.29% in Q2 2025 and bottomed at 184.91% in Q2 2022.
  • Average EBITDA Margin over 5 years is 50.37%, with a median of 37.59% recorded in 2023.
  • The sharpest move saw EBITDA Margin tumbled -13995bps in 2022, then skyrocketed 15014bps in 2023.
  • Year by year, EBITDA Margin stood at 49.29% in 2021, then plummeted by -129bps to 112.88% in 2022, then skyrocketed by 67bps to 37.39% in 2023, then soared by 34bps to 24.77% in 2024, then fell by -21bps to 29.91% in 2025.
  • Business Quant data shows EBITDA Margin for XGN at 29.91% in Q4 2025, 17.98% in Q3 2025, and 15.29% in Q2 2025.